Walmart (WMT$146.53) earnings forecast on February 21
On Tuesday, February 21, Walmart will be announcing its earnings forecast for the upcoming year. This is a highly anticipated event, as Walmart is one of the largest retailers in the world, and its performance often reflects broader trends in the global economy.
Walmart's most recent earnings report, released in November 2022, showed strong growth in e-commerce sales, which increased by 43% compared to the same quarter the previous year. However, the company also reported slower growth in physical store sales, with a 1.9% increase compared to the same quarter the previous year.
Investors will be looking closely at Walmart's earnings forecast to see how the company expects to perform in the coming year. With the ongoing COVID-19 pandemic continuing to impact the retail industry, it's likely that Walmart's e-commerce sales will remain strong, as consumers continue to do more of their shopping online. However, the company may continue to struggle with growth in physical stores, particularly as the pandemic has led to changes in consumer behavior.
Overall, Walmart's earnings forecast will be an important indicator of the health of the retail industry, as well as broader trends in the global economy. Investors and analysts will be paying close attention to the company's performance, looking for signs of continued growth and adaptation to the changing retail landscape.
Momentum Indicator for CVS turns positive, indicating new upward trend
CVS saw its Momentum Indicator move above the 0 level on September 17, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for CVS crossed bullishly above the 50-day moving average on August 14, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CVS advanced for three days, in of 330 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 219 cases where CVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for CVS moved out of overbought territory on September 08, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where CVS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CVS turned negative on September 08, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CVS broke above its upper Bollinger Band on August 15, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.213) is normal, around the industry mean (4.099). P/E Ratio (20.613) is within average values for comparable stocks, (16.800). Projected Growth (PEG Ratio) (0.613) is also within normal values, averaging (0.871). CVS has a moderately high Dividend Yield (0.036) as compared to the industry average of (0.023). P/S Ratio (0.242) is also within normal values, averaging (0.652).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. CVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an integrated pharmacy health care provider
Industry PublishingBooksMagazines
Advertisement